Therapure Biopharma Inc. today announced that a joint venture between 3SBio Inc., a leading global biotechnology company, and CPE Funds has entered into an agreement to acquire Therapure’s contract development and manufacturing (CDMO) business and certain rights to plasma products and technology for the Chinese market for US$290 million, subject to certain adjustments.

“Therapure is a business that we started from scratch and through a focused corporate strategy and discipline we have built the leading Canadian biomanufacturing operator and established a great product pipeline that is entering a new value creation stage as an independent company.”

— Gabriel de Alba, Chairman of Therapure and Managing Director and Partner at Catalyst

For the full press release, click here